Most target-date series invest in an array of their providers’ proprietary strategies, so it’s critical to consider each firm’s range of expertise. One way to do that is to examine the broad ...

Deep generative models are gaining attention in the field of de novo drug design. However, the rational design of ligand molecules for novel targets remains challenging, particularly in controlling ...